patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_806489 | REC_0008501 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 34 | 11.2 | 49 | male | 0 | 15 | 5.1 | 6 | entrectinib 600 mg daily | 17.4 | true | MSI-H | 2026-03-15T05:35:58.948699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_227014 | REC_0008502 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.4 | 68 | female | 0 | 15 | 7.2 | 4 | alectinib 600 mg BID | 17.5 | true | MSS | 2026-03-15T05:35:58.948931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535135 | REC_0008503 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 4.8 | 69 | female | 0 | 41 | 7.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 16.6 | false | MSS | 2026-03-15T05:35:58.949206+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_922344 | REC_0008504 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 25 | 11.8 | 58 | female | 1 | 20 | 4.7 | 0 | alectinib 600 mg BID | 12.8 | true | MSI-H | 2026-03-15T05:35:58.949445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916843 | REC_0008505 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 3.6 | 61 | female | 1 | 43 | 5.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 6.5 | true | MSS | 2026-03-15T05:35:58.949677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_336814 | REC_0008506 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 17.1 | 62 | female | 1 | 12 | 6 | 6 | osimertinib 80 mg daily | 9.2 | false | MSS | 2026-03-15T05:35:58.949912+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_982620 | REC_0008507 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7 | 54 | female | 0 | 60 | 6.1 | 8 | carboplatin + paclitaxel + pembrolizumab | 8.1 | false | MSS | 2026-03-15T05:35:58.950146+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176568 | REC_0008508 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 29 | 9.2 | 69 | male | 1 | 7 | 7.7 | 0 | osimertinib 80 mg daily | 31.7 | true | MSS | 2026-03-15T05:35:58.950377+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590550 | REC_0008509 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 5 | 68 | female | 0 | 40 | 6.4 | 1 | pembrolizumab 200 mg q3w | 23.6 | false | MSS | 2026-03-15T05:35:58.950606+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_793101 | REC_0008510 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 39 | 13.5 | 63 | male | 0 | 14 | 7.4 | 7 | alectinib 600 mg BID | 11 | true | MSS | 2026-03-15T05:35:58.950840+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_766477 | REC_0008511 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 9 | 81 | female | 1 | 18 | 6.7 | 4 | entrectinib 600 mg daily | 15.5 | true | MSS | 2026-03-15T05:35:58.951067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_473473 | REC_0008512 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 5.8 | 62 | male | 1 | 23 | 6.1 | 5 | entrectinib 600 mg daily | 7.9 | false | MSS | 2026-03-15T05:35:58.951298+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_946198 | REC_0008513 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 28 | 13.4 | 54 | male | 0 | 18 | 4.5 | 0 | entrectinib 600 mg daily | 52.4 | false | MSI-H | 2026-03-15T05:35:58.951530+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994010 | REC_0008514 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 12.9 | 63 | female | 0 | 16 | 4.5 | 4 | entrectinib 600 mg daily | 15.1 | false | MSI-H | 2026-03-15T05:35:58.951767+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_883703 | REC_0008515 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 3.7 | 64 | female | 0 | 11 | 3.6 | 5 | sotorasib 960 mg daily | 16.3 | true | MSS | 2026-03-15T05:35:58.952001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_837827 | REC_0008516 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 18.9 | 72 | female | 0 | 21 | 3.9 | 1 | osimertinib 80 mg daily | 7.4 | false | MSI-H | 2026-03-15T05:35:58.952303+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_357099 | REC_0008517 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 15.6 | 61 | female | 0 | 14 | 5.1 | 1 | pembrolizumab 200 mg q3w | 22.6 | true | MSS | 2026-03-15T05:35:58.952543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_827043 | REC_0008518 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 7.9 | 71 | female | 0 | 15 | 7.5 | 1 | sotorasib 960 mg daily | 26.2 | false | MSS | 2026-03-15T05:35:58.952772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645204 | REC_0008519 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 9.8 | 62 | female | 0 | 12 | 7.1 | 5 | sotorasib 960 mg daily | 4.8 | true | MSS | 2026-03-15T05:35:58.953007+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_279734 | REC_0008520 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 10.8 | 74 | female | 2 | 22 | 4.4 | 5 | entrectinib 600 mg daily | 15.4 | true | MSS | 2026-03-15T05:35:58.953238+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_751175 | REC_0008521 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 12.2 | 79 | female | 0 | 16 | 4.5 | 7 | osimertinib 80 mg daily | 12.3 | false | MSI-H | 2026-03-15T05:35:58.953478+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955501 | REC_0008522 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 9 | 58 | female | 1 | 18 | 6.8 | 3 | entrectinib 600 mg daily | 14.7 | false | MSS | 2026-03-15T05:35:58.953710+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826635 | REC_0008523 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 14.6 | 53 | male | 0 | 18 | 8.8 | 6 | sotorasib 960 mg daily | 16.7 | true | MSS | 2026-03-15T05:35:58.953942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556214 | REC_0008524 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 10.4 | 83 | female | 1 | 17 | 5.2 | 1 | sotorasib 960 mg daily | 12.7 | true | MSS | 2026-03-15T05:35:58.954173+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_380150 | REC_0008525 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 8.6 | 63 | female | 1 | 13 | 4.7 | 6 | osimertinib 80 mg daily | 13.6 | true | MSS | 2026-03-15T05:35:58.954405+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_172669 | REC_0008526 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 18.6 | 70 | female | 4 | 16 | 5.6 | 6 | osimertinib 80 mg daily | 12.8 | true | MSS | 2026-03-15T05:35:58.954636+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_311558 | REC_0008527 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 13.5 | 66 | female | 0 | 19 | 4.7 | 4 | alectinib 600 mg BID | 11.6 | true | MSI-H | 2026-03-15T05:35:58.954867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991672 | REC_0008528 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 9.3 | 73 | female | 1 | 11 | 4.4 | 3 | pembrolizumab 200 mg q3w | 11.3 | true | MSS | 2026-03-15T05:35:58.955094+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_225894 | REC_0008529 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 8.3 | 88 | male | 1 | 9 | 2.4 | 4 | pembrolizumab 200 mg q3w | 10.8 | true | MSS | 2026-03-15T05:35:58.955369+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_526552 | REC_0008530 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 11.9 | 55 | female | 0 | 23 | 7.4 | 1 | alectinib 600 mg BID | 11 | false | MSS | 2026-03-15T05:35:58.955609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207042 | REC_0008531 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 15 | 13.1 | 58 | female | 0 | 26 | 5.9 | 5 | sotorasib 960 mg daily | 15.1 | true | MSI-H | 2026-03-15T05:35:58.955847+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_550709 | REC_0008532 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 26 | 5.6 | 73 | female | 2 | 16 | 5.3 | 0 | carboplatin + paclitaxel + pembrolizumab | 22.8 | false | MSS | 2026-03-15T05:35:58.956190+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641662 | REC_0008533 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 32 | 5.5 | 76 | female | 1 | 31 | 4.4 | 5 | pembrolizumab 200 mg q3w | 17.5 | false | MSS | 2026-03-15T05:35:58.956435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_216406 | REC_0008534 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 15 | 63 | male | 1 | 18 | 5 | 1 | entrectinib 600 mg daily | 9.7 | true | MSI-H | 2026-03-15T05:35:58.956675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_966067 | REC_0008535 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 12.4 | 69 | female | 1 | 19 | 4.5 | 3 | sotorasib 960 mg daily | 20.7 | false | MSI-H | 2026-03-15T05:35:58.956909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623000 | REC_0008536 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 7.5 | 70 | female | 3 | 23 | 6.5 | 6 | pembrolizumab 200 mg q3w | 12.6 | false | MSS | 2026-03-15T05:35:58.957139+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532029 | REC_0008537 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 7.6 | 65 | female | 1 | 26 | 5.6 | 2 | alectinib 600 mg BID | 9.8 | true | MSS | 2026-03-15T05:35:58.957373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_404779 | REC_0008538 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 11 | 65 | female | 1 | 18 | 6.9 | 5 | osimertinib 80 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:58.957607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839139 | REC_0008539 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 16.5 | 75 | male | 2 | 6 | 7.4 | 5 | entrectinib 600 mg daily | 14.7 | false | MSS | 2026-03-15T05:35:58.957839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932060 | REC_0008540 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 33 | 11.9 | 51 | female | 0 | 5 | 4.9 | 1 | alectinib 600 mg BID | 8.3 | true | MSS | 2026-03-15T05:35:58.958074+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500234 | REC_0008541 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 11.4 | 70 | female | 2 | 21 | 3.5 | 4 | osimertinib 80 mg daily | 16.5 | false | MSS | 2026-03-15T05:35:58.958308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_886468 | REC_0008542 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 14.8 | 52 | male | 0 | 20 | 3.5 | 2 | pembrolizumab 200 mg q3w | 6.2 | false | MSS | 2026-03-15T05:35:58.958587+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466160 | REC_0008543 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 13.1 | 72 | female | 2 | 12 | 5.2 | 2 | sotorasib 960 mg daily | 20.8 | false | MSI-H | 2026-03-15T05:35:58.958825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347348 | REC_0008544 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 9 | 75 | female | 1 | 15 | 5.1 | 7 | alectinib 600 mg BID | 5.1 | true | MSS | 2026-03-15T05:35:58.959054+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685833 | REC_0008545 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 16.5 | 60 | female | 1 | 18 | 8.1 | 4 | osimertinib 80 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:58.959289+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_867753 | REC_0008546 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 7.5 | 80 | female | 2 | 10 | 6.8 | 6 | alectinib 600 mg BID | 9 | false | MSS | 2026-03-15T05:35:58.959515+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_263952 | REC_0008547 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 12.8 | 58 | male | 0 | 11 | 5 | 1 | osimertinib 80 mg daily | 26.4 | false | MSS | 2026-03-15T05:35:58.959751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_624958 | REC_0008548 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 16 | 12 | 74 | female | 2 | 4 | 6.6 | 5 | sotorasib 960 mg daily | 4.8 | true | MSS | 2026-03-15T05:35:58.959980+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702187 | REC_0008549 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 13.5 | 75 | male | 1 | 14 | 5.9 | 7 | osimertinib 80 mg daily | 12.2 | false | MSI-H | 2026-03-15T05:35:58.960276+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641427 | REC_0008550 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 10.8 | 62 | female | 1 | 8 | 5.6 | 4 | alectinib 600 mg BID | 8 | true | MSI-H | 2026-03-15T05:35:58.960520+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956158 | REC_0008551 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 9.6 | 65 | female | 0 | 16 | 7.3 | 1 | osimertinib 80 mg daily | 17.3 | false | MSS | 2026-03-15T05:35:58.960758+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_873145 | REC_0008552 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 13.8 | 80 | female | 2 | 20 | 6.9 | 1 | entrectinib 600 mg daily | 7.5 | true | MSI-H | 2026-03-15T05:35:58.960988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_706210 | REC_0008553 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 7.5 | 64 | female | 1 | 13 | 5.1 | 4 | alectinib 600 mg BID | 15.4 | true | MSS | 2026-03-15T05:35:58.961220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850938 | REC_0008554 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 5.8 | 61 | male | 0 | 16 | 2.5 | 7 | alectinib 600 mg BID | 9.1 | false | MSS | 2026-03-15T05:35:58.961453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149059 | REC_0008555 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 9.8 | 61 | female | 1 | 17 | 4.3 | 5 | entrectinib 600 mg daily | 10.7 | false | MSS | 2026-03-15T05:35:58.961738+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_380225 | REC_0008556 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 10.9 | 70 | male | 3 | 10 | 3.5 | 5 | osimertinib 80 mg daily | 16.8 | false | MSI-H | 2026-03-15T05:35:58.961975+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_478097 | REC_0008557 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 26 | 7 | 69 | female | 0 | 49 | 5 | 1 | pembrolizumab 200 mg q3w | 14.3 | false | MSS | 2026-03-15T05:35:58.962206+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_825110 | REC_0008558 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 7.3 | 68 | female | 0 | 52 | 7.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 5.8 | false | MSS | 2026-03-15T05:35:58.962433+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_129203 | REC_0008559 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 3.6 | 57 | female | 0 | 26 | 6.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 6.7 | true | MSS | 2026-03-15T05:35:58.962665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275284 | REC_0008560 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 15 | 18.6 | 67 | female | 1 | 22 | 4.8 | 2 | entrectinib 600 mg daily | 18.9 | false | MSI-H | 2026-03-15T05:35:58.962898+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_985825 | REC_0008561 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 33 | 18.9 | 61 | male | 0 | 9 | 5.1 | 3 | sotorasib 960 mg daily | 4.5 | true | MSI-H | 2026-03-15T05:35:58.963134+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986414 | REC_0008562 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 20 | 4.6 | 80 | female | 1 | 36 | 6 | 1 | pembrolizumab 200 mg q3w | 19.6 | false | MSS | 2026-03-15T05:35:58.963360+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146918 | REC_0008563 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 4 | 69 | male | 1 | 45 | 4.9 | 5 | pembrolizumab 200 mg q3w | 16.9 | false | MSS | 2026-03-15T05:35:58.963595+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_588579 | REC_0008564 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 7.8 | 65 | female | 1 | 12 | 6.7 | 7 | entrectinib 600 mg daily | 6.5 | false | MSS | 2026-03-15T05:35:58.963826+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720516 | REC_0008565 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 9.5 | 85 | female | 1 | 28 | 5.2 | 7 | alectinib 600 mg BID | 10.5 | true | MSS | 2026-03-15T05:35:58.964052+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190946 | REC_0008566 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 8.5 | 60 | female | 1 | 32 | 7.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 9.2 | false | MSS | 2026-03-15T05:35:58.964335+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_187154 | REC_0008567 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 11.3 | 77 | female | 2 | 14 | 5.9 | 4 | osimertinib 80 mg daily | 10.5 | true | MSI-H | 2026-03-15T05:35:58.964572+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_451460 | REC_0008568 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 15.7 | 61 | male | 1 | 14 | 4.4 | 2 | entrectinib 600 mg daily | 17.1 | true | MSS | 2026-03-15T05:35:58.964872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850936 | REC_0008569 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 12.4 | 66 | female | 1 | 21 | 5.6 | 3 | alectinib 600 mg BID | 14.4 | true | MSI-H | 2026-03-15T05:35:58.965109+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245299 | REC_0008570 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 12.6 | 67 | female | 0 | 14 | 5.5 | 6 | entrectinib 600 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:58.965342+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_253290 | REC_0008571 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 7.7 | 72 | female | 2 | 14 | 5.9 | 5 | entrectinib 600 mg daily | 10.5 | true | MSS | 2026-03-15T05:35:58.965572+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_948259 | REC_0008572 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 11.3 | 80 | female | 2 | 7 | 3 | 5 | alectinib 600 mg BID | 13.6 | false | MSI-H | 2026-03-15T05:35:58.965806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756024 | REC_0008573 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 1.9 | 54 | female | 0 | 42 | 6 | 3 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:58.966036+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116268 | REC_0008574 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 7.2 | 63 | male | 1 | 13 | 5.2 | 1 | alectinib 600 mg BID | 14.7 | true | MSS | 2026-03-15T05:35:58.966266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_486685 | REC_0008575 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 7.4 | 68 | male | 0 | 19 | 5.4 | 2 | osimertinib 80 mg daily | 18.7 | false | MSS | 2026-03-15T05:35:58.966499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_544477 | REC_0008576 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 8.6 | 74 | female | 2 | 3 | 5.9 | 6 | alectinib 600 mg BID | 11.8 | true | MSS | 2026-03-15T05:35:58.966727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519389 | REC_0008577 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 13.3 | 66 | female | 0 | 15 | 6.3 | 5 | alectinib 600 mg BID | 10.1 | false | MSS | 2026-03-15T05:35:58.966963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_923969 | REC_0008578 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 18.6 | 73 | male | 1 | 16 | 5.5 | 1 | sotorasib 960 mg daily | 21 | false | MSS | 2026-03-15T05:35:58.967196+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_835851 | REC_0008579 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 4.4 | 65 | female | 1 | 40 | 8.2 | 6 | pembrolizumab 200 mg q3w | 9.7 | false | MSS | 2026-03-15T05:35:58.967428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660998 | REC_0008580 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 2.8 | 55 | male | 0 | 8 | 7.8 | 4 | pembrolizumab 200 mg q3w | 15.1 | true | MSS | 2026-03-15T05:35:58.967661+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_110311 | REC_0008581 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 4.2 | 63 | female | 1 | 33 | 4.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.4 | false | MSS | 2026-03-15T05:35:58.967945+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944014 | REC_0008582 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 8.3 | 70 | female | 2 | 5 | 5.2 | 1 | pembrolizumab 200 mg q3w | 18 | true | MSS | 2026-03-15T05:35:58.968271+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_822312 | REC_0008583 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 8.3 | 73 | female | 1 | 11 | 5 | 1 | pembrolizumab 200 mg q3w | 19.6 | false | MSS | 2026-03-15T05:35:58.968508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_766264 | REC_0008584 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 11.7 | 63 | male | 0 | 14 | 7.9 | 6 | alectinib 600 mg BID | 4.5 | false | MSI-H | 2026-03-15T05:35:58.968744+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_515172 | REC_0008585 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 10.9 | 66 | female | 0 | 0 | 6 | 3 | entrectinib 600 mg daily | 8.2 | true | MSS | 2026-03-15T05:35:58.968980+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239706 | REC_0008586 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 33 | 18.6 | 73 | female | 3 | 13 | 6 | 0 | osimertinib 80 mg daily | 25.4 | false | MSI-H | 2026-03-15T05:35:58.969214+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711604 | REC_0008587 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 13.9 | 78 | female | 2 | 14 | 7.2 | 2 | alectinib 600 mg BID | 13.4 | false | MSI-H | 2026-03-15T05:35:58.969444+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664463 | REC_0008588 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 9.3 | 62 | female | 0 | 40 | 3.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.3 | true | MSS | 2026-03-15T05:35:58.969675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_274274 | REC_0008589 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 19.5 | 54 | male | 0 | 21 | 6.7 | 8 | entrectinib 600 mg daily | 11 | false | MSI-H | 2026-03-15T05:35:58.969911+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190176 | REC_0008590 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 12.8 | 77 | female | 2 | 12 | 5.3 | 6 | osimertinib 80 mg daily | 7.4 | true | MSS | 2026-03-15T05:35:58.970146+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939938 | REC_0008591 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 11 | 62 | female | 1 | 26 | 5.4 | 2 | osimertinib 80 mg daily | 21 | false | MSI-H | 2026-03-15T05:35:58.970383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_490836 | REC_0008592 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 2.8 | 72 | female | 3 | 0 | 7.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 23.3 | false | MSS | 2026-03-15T05:35:58.970610+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_251763 | REC_0008593 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 6.4 | 54 | male | 0 | 31 | 5.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.7 | false | MSS | 2026-03-15T05:35:58.970841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317888 | REC_0008594 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 11 | 70 | female | 1 | 17 | 5.3 | 6 | alectinib 600 mg BID | 4 | true | MSI-H | 2026-03-15T05:35:58.971120+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533461 | REC_0008595 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 13.4 | 59 | female | 1 | 11 | 6.8 | 4 | osimertinib 80 mg daily | 6.6 | true | MSI-H | 2026-03-15T05:35:58.971357+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791869 | REC_0008596 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 5.4 | 84 | female | 1 | 47 | 8.2 | 5 | pembrolizumab 200 mg q3w | 13.9 | true | MSS | 2026-03-15T05:35:58.971585+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634624 | REC_0008597 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 4.5 | 67 | female | 0 | 35 | 5.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 8 | false | MSS | 2026-03-15T05:35:58.971820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_455927 | REC_0008598 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 13.8 | 73 | female | 1 | 27 | 5.2 | 5 | alectinib 600 mg BID | 6.3 | false | MSI-H | 2026-03-15T05:35:58.972051+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_188309 | REC_0008599 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 6.7 | 80 | female | 2 | 13 | 7.2 | 5 | sotorasib 960 mg daily | 13.1 | false | MSS | 2026-03-15T05:35:58.972325+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712416 | REC_0008600 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.1 | 63 | male | 0 | 45 | 5.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.4 | true | MSS | 2026-03-15T05:35:58.972572+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.